1-2 of 2
G. Doug Myers
Close
Sort by
Journal Articles

Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia

Amy Moskop, Lauren Pommert, Christina Baggott, Snehit Prabhu, Holly L. Pacenta, Christine L. Phillips, Jenna Rossoff, Heather E. Stefanski, Julie-An Talano, Steve P. Margossian, Michael R. Verneris, G. Doug Myers, Nicole A. Karras, Patrick A. Brown, Muna Qayed, Michelle L. Hermiston, Prakash Satwani, Christa Krupski, Amy K. Keating, Rachel Wilcox, Cara A. Rabik, Vanessa A. Fabrizio, Vasant Chinnabhandar, A. Yasemin Goksenin, Kevin J. Curran, Crystal L. Mackall, Theodore W. Laetsch, Erin M. Guest, Erin H. Breese, Liora M. Schultz
Journal: Blood Advances
Blood Adv (2022) 6 (14): 4251–4255.
https://doi.org/10.1182/bloodadvances.2021006393
Published: 2022
Journal Articles

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma

Clinical Trials & Observations
Karen Thudium Mueller, Stephan A. Grupp, Shannon L. Maude, John E. Levine, Michael A. Pulsipher, Michael W. Boyer, Keith J. August, G. Doug Myers, Constantine S. Tam, Ulrich Jaeger, Stephen Ronan Foley, Peter Borchmann, Stephen J. Schuster, Edmund K. Waller, Rakesh Awasthi, Bernd Potthoff, Andy Warren, Edward R. Waldron, Fraser McBlane, Andrea Chassot-Agostinho, Theodore W. Laetsch
Journal: Blood Advances
Blood Adv (2021) 5 (23): 4980–4991.
https://doi.org/10.1182/bloodadvances.2020003844
Published: 2021
Includes: Supplemental data